measles virus vaccine

Generic Name: measles virus vaccine (MEE sels VYE rus vax EEN)

Brand Names: Attenuvax

What is measles virus vaccine?

Measles is a serious disease caused by a virus. It is spread from person to person through the air.

Measles virus can cause minor symptoms such as skin rash, cough, runny nose, eye irritation, or mild fever. It can also cause more serious symptoms such as ear infection, pneumonia, seizures, permanent brain damage, or death.

The measles virus vaccine is a live-virus vaccine used to help prevent this disease in children and adults.

This vaccine works by exposing you to a small dose of the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

Measles virus vaccine is for use in adults and children who are at least 12 months old, and in adults who have never received the vaccine or had the diseases.

Like any vaccine, the measles virus vaccine may not provide protection from disease in every person.

What is the most important information I should know about this vaccine?

You should not receive this vaccine if you are allergic to gelatin or neomycin (Mycifradin, Neo-Fradin, Neo-Tab), or if you have ever had a life-threatening allergic reaction to any vaccine containing the measles virus.

You should also not receive this vaccine if you have a weak immune system, or if you have leukemia, lymphoma, bone marrow cancer, or if you are pregnant.

You should not receive a measles virus vaccine if you are pregnant. Wait until after your child is born to receive the vaccine.

Avoid becoming pregnant for at least 3 months after receiving a measles virus vaccine.

Do not receive this vaccine without telling your doctor if you are breast-feeding a baby.

Before receiving this vaccine, tell the doctor if you are allergic to eggs, or if you have thrombocytopenia purpura, untreated tuberculosis, a history of seizures or head injury, or if you have received an immune globulin or other blood product within the past 3 months.

The measles vaccine is usually given to a child who is 12 to 15 month old. A measles, mumps, and rubella (MMR) vaccine should then be given before the child starts elementary school.

Your individual booster schedule may be different from these guidelines. In addition to the measles virus vaccine, you may also need to receive a measles, mumps, and rubella (MMR) vaccination. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.

Be sure you receive all recommended doses of this vaccine. If you do not receive the full series of vaccines, you may not be fully protected against the disease.

You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot.

Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shots caused any side effects.

Becoming infected with measles is much more dangerous to your health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.

What should I discuss with my healthcare provider before receiving this vaccine?

You should not receive this vaccine if you are allergic to:

• 
  

  gelatin;

  
  


• 
  

  neomycin (Mycifradin, Neo-Fradin, Neo-Tab); or

  
  


• 
  

  if you have ever had a life-threatening allergic reaction to any vaccine containing the measles virus.

  
  

You should also not receive this vaccine if you have:

• 
  

  severe immune suppression caused by certain medications, or by receiving chemotherapy or radiation;

  
  


• 
  

  a weak immune system caused by disease (such as cancer, HIV, or AIDS), bone marrow transplant, or by using certain medicines or receiving cancer treatments;

  
  


• 
  

  leukemia, lymphoma, or any cancer that affects the bone marrow or lymph nodes; or

  
  


• 
  

  if you are pregnant.

  
  

Before receiving this vaccine, tell the doctor if you have:

• 
  

  allergy to eggs;

  
  


• 
  

  thrombocytopenia purpura (easy bruising or bleeding);

  
  


• 
  

  active and untreated tuberculosis infection;

  
  


• 
  

  a history of head or brain injury;

  
  


• 
  

  a personal or family history of seizures; or

  
  


• 
  

  if you have received an immune globulin or other blood product within the past 3 months.

  
  

You can still receive a vaccine if you have a minor cold or low fever. In the case of a more severe illness with a fever or any type of infection, wait until you get better before receiving this vaccine.

You should not receive a measles virus vaccine if you are pregnant. Wait until after your child is born to receive the vaccine.

Avoid becoming pregnant for at least 3 months after receiving a measles virus vaccine.

Do not receive this vaccine without telling your doctor if you are breast-feeding a baby.

How is this vaccine given?

This vaccine is given as an injection (shot) under your skin. You will receive this injection in a doctor's office or other clinic setting.

The measles vaccine is usually given to a child who is 12 to 15 month old. A measles, mumps, and rubella (MMR) vaccine should then be given before the child starts elementary school.

Children younger than 12 months old may be vaccinated against measles in an outbreak situation. If the child receives the first measles virus vaccine before the age of 12 months, a booster dose should be given between 12 and 15 months of age.

Your individual booster schedule may be different from these guidelines. In addition to the measles virus vaccine, you may also need to receive a measles, mumps, and rubella (MMR) vaccination. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.

It is especially important to prevent fever from occurring if you have a seizure disorder such as epilepsy.

This vaccine can cause false results on a skin test for tuberculosis. For a few weeks after vaccination, tell any doctor who treats you that you have received the measles virus vaccine.

What happens if I miss a dose?

Contact your doctor if you will miss a booster dose or if you get behind schedule. The next dose should be given as soon as possible. There is no need to start over.

Be sure you receive all recommended doses of this vaccine. If you do not receive the full series of vaccines, you may not be fully protected against the disease.

What happens if I overdose?

An overdose of this vaccine is unlikely to occur.

What should I avoid before or after receiving this vaccine?

Follow your doctor's instructions about any restrictions on food, beverages, or activity before or after you receive a measles vaccine.

Measles virus vaccines side effects

You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot. Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shots caused any side effects.

Becoming infected with measles is much more dangerous to your health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

• 
  

  high fever;

  
  


• 
  

  easy bruising or bleeding, unusual weakness;

  
  


• 
  

  severe blistering, peeling, and red skin rash;

  
  


• 
  

  seizure (convulsions);

  
  


• 
  

  weakness, numbness or tingly feeling in your feet and spreading upward;

  
  


• 
  

  problems with hearing or vision;

  
  


• 
  

  problems with eye movement, speech, swallowing, or bladder and bowel functions;

  
  


• 
  

  severe lower back pain; or

  
  


• 
  

  slow heart rate, trouble breathing, feeling like you might pass out.

  
  

Less serious side effects include:

• 
  

  redness, burning, stinging, swelling, blistering, or hives where the shot was given;

  
  


• 
  

  headache, dizziness;

  
  


• 
  

  feeling irritable;

  
  


• 
  

  fussiness, excessive crying;

  
  


• 
  

  low fever, cough, runny nose;

  
  


• 
  

  joint or muscle pain; or

  
  


• 
  

  nausea, vomiting, diarrhea.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1-800-822-7967.

Measles virus vaccine Dosing Information

Usual Adult Dose for Measles Prophylaxis:

0.5 mL administered subcutaneously, preferably into the outer aspect of the upper arm.

Usual Pediatric Dose for Measles Prophylaxis:

The recommended age for primary vaccination is 12 to 15 months:
0.5 mL administered subcutaneously, preferably into the outer aspect of the upper arm.

Children first vaccinated when younger than 12 months of age should receive another dose between 12 to 15 months of age followed by revaccination prior to elementary school entry.

What other drugs will affect measles virus vaccine?

Before receiving this vaccine, tell the doctor about all other vaccines you have recently received.

Also tell the doctor if you have recently received drugs or treatments that can weaken the immune system, including:

• 
  

  an oral, nasal, inhaled, topical, or injectable steroid medicine used for 2 weeks or longer;

  
  


• 
  

  medications to treat psoriasis, rheumatoid arthritis, or other autoimmune disorders, such as azathioprine (Imuran), efalizumab (Raptiva), etanercept (Enbrel), leflunomide (Arava), and others; or

  
  


• 
  

  medicines to treat or prevent organ transplant rejection, such as basiliximab (Simulect), cyclosporine (Sandimmune, Neoral, Gengraf), muromonab-CD3 (Orthoclone), mycophenolate mofetil (CellCept), sirolimus (Rapamune), or tacrolimus (Prograf).

  
  

If you are using any of these medications, you may not be able to receive a measles virus vaccine, or you may need to wait until the other treatments are finished.

This list is not complete and there may be other drugs that can affect this vaccine. Tell your doctor about all the prescription and over-the-counter medications you have received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

More measles virus vaccine resources

• Measles virus vaccine Side Effects (in more detail)
• Measles virus vaccine Use in Pregnancy & Breastfeeding
• Measles virus vaccine Drug Interactions
• Measles virus vaccine Support Group
• 0 Reviews for Measles virus vaccine - Add your own review/rating

• Measles Virus Vaccine MedFacts Consumer Leaflet (Wolters Kluwer)


• Attenuvax Advanced Consumer (Micromedex) - Includes Dosage Information

Compare measles virus vaccine with other medications

• Measles Prophylaxis

Where can I get more information?

• Your doctor or pharmacist may have information about this vaccine written for health professionals that you may read. You may also find additional information from your local health department or the Centers for Disease Control and Prevention.

See also: measles virus vaccine side effects (in more detail)

Vancomycin 1g Powder for Solution for Infusion (Wockhardt UK Ltd)

1. Name Of The Medicinal Product

Vancomycin 1g Powder for Solution for Infusion

2. Qualitative And Quantitative Composition

Each vial contains vancomycin 1g* (equivalent to 1 000 000* IU) as vancomycin hydrochloride

For full list of excipients, see 6.1

3. Pharmaceutical Form

Powder for solution for intravenous infusion

Powder for solution for oral use

'A white to cream coloured porous cake'

4. Clinical Particulars

4.1 Therapeutic Indications

Vancomycin is indicated in potentially life-threatening infections which cannot be treated with other effective, less toxic antimicrobial drugs, including the penicillins and cephalosporins.

Vancomycin is useful in the therapy of severe staphylococcal infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins, or who have infections with staphylococci resistant to other antibiotics.

Vancomycin is used in the treatment of endocarditis and as prophylaxis against endocarditis in patients at risk from dental or surgical procedures.

Its effectiveness has been documented in other infections due to staphylococci, including osteomyelitis, pneumonia, septicaemia and soft tissue infections.

Vancomycin may be used orally for the treatment of staphylococcal enterocolitis and pseudomembranous colitis due to Clostridium difficile. Parenteral administration of vancomycin is not effective for these indications. Intravenous administration may be used concomitantly if required.

4.2 Posology And Method Of Administration

For intravenous infusion and oral use only and not for intramuscular administration.

Please refer to Section 6.6 for full details on preparation.

Infusion-related adverse events are related to both concentration and rate of administration of vancomycin.

Concentrations of no more than 5mg/ml are recommended. In selected patients in need of fluid restriction, a concentration up to 10mg/ml may be used; use of such higher concentrations may increase the risk of infusion-related events. Infusions should be given over at least 60 minutes. In adults, if doses exceeding 500mg are used, a rate of infusion of no more than 10mg/min is recommended. Infusion-related events may occur, however, at any rate or concentration.

Intravenous infusion in patients with normal renal function

Adults: The usual intravenous dose is 500mg every six hours or 1g every 12 hours, in sodium chloride intravenous infusion or 5% dextrose intravenous infusion. Each dose should be administered at no more than 10mg/min. Other patient factors, such as age, obesity or pregnancy, may call for modification of the usual daily dose. The majority of patients with infections caused by organisms sensitive to the antibiotic show a therapeutic response within 48-72 hours. The total duration of therapy is determined by the type and severity of the infection and the clinical response of the patient. In staphylococcal endocarditis, treatment for three weeks or longer is recommended.

Pregnancy: It has been reported that significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant patients - Section 4.6 Pregnancy and lactation.

The elderly: Dosage reduction may be necessary to a greater extent than expected because of decreasing renal function (see below). Monitor auditory function - see Section 4.4.Special warnings and precautions for use.

Children: The usual intravenous dosage is 10mg/kg per dose given every six hours (total daily dosage 40mg/kg of body weight). Each dose should be administered over a period of at least 60 minutes.

In neonates and young infants, the total daily dosage may be lower. An initial dose of 15mg/kg is suggested, followed by 10mg/kg every 12 hours in the first week of life and every eight hours thereafter until one month of age. Each dose should be administered over 60 minutes. Close monitoring of serum vancomycin concentrations may be warranted in these patients.

Patients with impaired renal function

Dosage adjustments must be made to avoid toxic serum levels. In premature infants and the elderly, greater dosage reductions than expected may be necessary because of decreased renal function. Regular monitoring of serum levels is advised in such patients, as accumulation has been reported, especially after prolonged therapy. Vancomycin serum concentrations may be determined by use of a microbiological assay, radioimmunoassay, fluorescence polarisation immunoassay, fluorescence immunoassay or high-pressure liquid chromatography. The following nomogram, based on creatinine clearance values, is provided:

The nomogram is not valid for functionally anephric patients on dialysis. For such patients, a loading dose of 15mg/kg body weight should be given to achieve therapeutic serum levels promptly, and the dose required to maintain stable levels is 1.9mg/kg/24 hours. Since individual maintenance doses of 250mg to 1g are convenient, in patients with marked renal impairment a dose may be given every several days rather than on a daily basis. In anuria a dose of 1g every seven to ten days has been recommended.

For instructions on the preparation of solutions, See Section 6.6.

Measurement of serum concentrations

Following multiple intravenous doses, peak serum concentrations, measured two hours after infusion is complete, range from 18-26mg/l. Trough levels measured immediately prior to the next dose should be 5-10mg/l. Ototoxicity has been associated with serum drug levels of 80-100mg/l, but this is rarely seen when serum levels are kept at or below 30mg/l.

Oral administration

The contents of vials for parenteral administration may be used.

Adults and the elderly: The usual daily dose given is 500mg in divided doses for seven to ten days, although up to 2g/day have been used in severe cases. The total daily dosage should not exceed 2g. Each dose may be reconstituted in 30ml water and either given to the patient to drink, or administered by nasogastric tube.

Children: The usual daily dose is 40mg/kg in three or four divided doses for seven to ten days. The total daily dosage should not exceed 2g.

Common flavouring syrups may be added to the solution at the time of administration to improve the taste.

4.3 Contraindications

Hypersensitivity to vancomycin.

4.4 Special Warnings And Precautions For Use

Warnings

Rapid bolus administration (eg, over several minutes) may be associated with exaggerated hypotension, including shock, and, rarely, cardiac arrest. Vancomycin should be infused in a dilute solution over a period of not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions (see Section 4.2. Posology and method of administration and Section 4.8 Undesirable effects).

Some patients with inflammatory disorders of the intestinal mucosa may have significant systemic absorption of oral vancomycin and, therefore, may be at risk for the development of adverse reactions associated with the parenteral administration of vancomycin. The risk is greater in patients with renal impairment. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly.

Due to its potential ototoxicity and nephrotoxicity, vancomycin should be used with care in patients with renal insufficiency and the dose should be reduced according to the degree of renal impairment. The risk of toxicity is appreciably increased by high blood concentrations or prolonged therapy. Blood levels should be monitored and renal function tests should be performed regularly.

Vancomycin should also be avoided in patients with previous hearing loss. If it is used in such patients, the dose should be regulated, if possible, by periodic determination of the drug level in the blood. Deafness may be preceded by tinnitus. The elderly are more susceptible to auditory damage. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment.

Use in paediatrics: In premature neonates and young infants, it may be appropriate to confirm desired vancomycin serum concentrations. Concomitant administration of vancomycin and anaesthetic agents has been associated with erythema and histamine-like flushing in children.

Use in the elderly: The natural decrement of glomerular filtration with increasing age may lead to elevated vancomycin serum concentrations if dosage is not adjusted (see Section 4.2 Posology and method of administration).

Precautions

Clinically significant serum concentrations have been reported in some patients being treated for active C. difficile-induced pseudomembranous colitis after multiple oral doses of vancomycin. Therefore, monitoring of serum concentrations may be appropriate in these patients.

Patients with borderline renal function and individuals over the age of 60 should be given serial tests of auditory function and of vancomycin blood levels. All patients receiving the drug should have periodic haematological studies, urine analysis and renal function tests.

Vancomycin is very irritating to tissue, and causes injection site necrosis when injected intramuscularly; it must be infused intravenously. Injection site pain and thrombophlebitis occur in many patients receiving vancomycin and are occasionally severe.

The frequency and severity of thrombophlebitis can be minimised by administering the drug slowly as a dilute solution (2.5 to 5.0g/l) and by rotating the sites of infusion.

Prolonged use of vancomycin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. In rare instances, there have been reports of pseudomembranous colitis, due to C. difficile, developing in patients who received intravenous vancomycin.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Concomitant administration of vancomycin and anaesthetic agents has been associated with erythema, histamine-like flushing and anaphylactoid reactions.

There have been reports that the frequency of infusion-related events increases with the concomitant administration of anaesthetic agents. Infusion-related events may be minimised by the administration of vancomycin as a 60-minute infusion prior to anaesthetic induction.

Concurrent or sequential systemic or topical use of other potentially neurotoxic or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymixin B, colistin, viomycin or cisplatin, when indicated, requires careful monitoring.

4.6 Pregnancy And Lactation

Use in pregnancy: Teratology studies have been performed at five times the human dose in rats and three times the human dose in rabbits, and have revealed no evidence of harm to the foetus due to vancomycin. In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin hydrochloride on infants were evaluated when the drug was administered to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. Vancomycin hydrochloride was found in cord blood. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. One infant, whose mother received vancomycin in the third trimester, experienced conductive hearing loss that was not attributable to vancomycin. Because vancomycin was administered only in the second and third trimesters, it is not known whether it causes foetal harm. Vancomycin should be given in pregnancy only if clearly needed and blood levels should be monitored carefully to minimise the risk of foetal toxicity. It has been reported, however, that pregnant patients may require significantly increased doses of vancomycin to achieve therapeutic serum concentrations.

Use in nursing mothers: Vancomycin hydrochloride is excreted in human milk. Caution should be exercised when vancomycin is administered to a nursing woman. It is unlikely that a nursing infant can absorb a significant amount of vancomycin from its gastro-intestinal tract.

4.7 Effects On Ability To Drive And Use Machines

Not applicable

4.8 Undesirable Effects

Infusion-related events: During or soon after rapid infusion of vancomycin, patients may develop anaphylactoid reactions including hypotension, wheezing, dyspnoea, urticaria or pruritus. Rapid infusion may also cause flushing of the upper-body ('red-neck syndrome') or pain and muscle spasm of the chest and back. These reactions usually resolve within 20 minutes but may persist for several hours. In animal studies, hypotension and bradycardia occurred in animals given large doses of vancomycin at high concentrations and rates. Such events are infrequent if vancomycin is given by slow infusion over 60 minutes. In studies of normal volunteers, infusion-related events did not occur when vancomycin was administered at a rate of 10mg/min or less.

Nephrotoxicity: Rarely, renal failure, principally manifested by increased serum creatinine or blood urea concentrations, have been observed, especially in patients given large doses of intravenously administered vancomycin. Rare cases of interstitial nephritis have been reported. Most occurred in patients who were given aminoglycosides concomitantly or who had pre-existing kidney dysfunction. When vancomycin was discontinued, azotaemia resolved in most patients.

Ototoxicity: Hearing loss associated with intravenously administered vancomycin has been reported. Most of these patients had kidney dysfunction, pre-existing hearing loss, or concomitant treatment with an ototoxic drug. Vertigo, dizziness and tinnitus have been reported rarely.

Haematological: Reversible neutropenia, usually starting one week or more after onset of intravenous therapy or after a total dose of more than 25g. Neutropenia appears to be promptly reversible when vancomycin is discontinued. Thrombocytopenia has rarely been reported. Reversible agranulocytosis (less than 500 granulocytes per mm³) has been reported rarely, although causality has not been established.

Miscellaneous: Phlebitis, hypersensitivity reactions, anaphylaxis, nausea, chills, drug fever, eosinophilia, rashes (including exfoliative dermatitis) and rare cases of vasculitis. Vancomycin has been associated with the bullous eruption disorders, Stevens-Johnson syndrome, toxic epidermal necrolysis and linear IgA bullous dermatosis. If a bullous disorder is suspected, the drug should be discontinued and specialist dermatological assessment should be carried out.

4.9 Overdose

Supportive care is advised, with maintenance of glomerular filtration. Vancomycin is poorly removed from the blood by haemodialysis or peritoneal dialysis. Haemoperfusion with Amberlite resin XAD-4 has been reported to be of limited benefit.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

ATC Code: JO1X A (Glycopeptide antibacterial)

Vancomycin is a glycopeptide antibiotic derived from Nocardia orientalis (formerly Streptomyces orientalis), and is active against many Gram-positive bacteria, including Staphylococcus aureus, Staph. epidermidis, alpha and beta haemolytic streptococci, group D streptococci, corynebacteria and clostridia.

5.2 Pharmacokinetic Properties

Vancomycin is not significantly absorbed from the normal gastro-intestinal tract and is therefore not effective by the oral route for infections other than staphylococcal enterocolitis and pseudomembranous colitis due to Clostridium difficile.

5.3 Preclinical Safety Data

Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no mutagenic potential of vancomycin was found in standard laboratory tests. No definitive fertility studies have been performed.

6. Pharmaceutical Particulars

6.1 List Of Excipients

None

6.2 Incompatibilities

Vancomycin solution has a low pH that may cause chemical or physical instability when it is mixed with other compounds.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf Life

Unopened - 36 months

Reconstituted solution intended for parenteral administration

Physical and chemical stability have been demonstrated for a period of 24 hours when stored at 2° to 8°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.

Prior to administration, parenteral drug products should be inspected visually for particulate matter and discolouration whenever solution or container permits.

Reconstituted solution intended for oral administration

Solution intended for oral administration may be stored in a refrigerator (2° to 8°C) for up to 24 hours.

6.4 Special Precautions For Storage

Unopened: Do not store above 25°C

After reconstitution: Store at 2-8^oC (see 6.3 Shelf Life).

6.5 Nature And Contents Of Container

Packs* of one, two, five or ten Type II colourless glass 20ml vials stoppered with Type I rubber stopper, capped with a flip-off cap.

*Not all pack sizes may be marketed

6.6 Special Precautions For Disposal And Other Handling

Preparation of solution: At the time of use, add 20ml of water for injections to the 1g vial. Vials reconstituted in this manner will give a solution of 50mg/ml.

The reconstituted solution is clear and colourless.

Further dilution is required. Read instructions which follow:

1. Intermittent infusion is the preferred method of administration. Reconstituted solutions containing 1g vancomycin must be diluted with at least 200ml diluent. 0.9% sodium chloride intravenous infusion or 5% dextrose intravenous infusion are suitable diluents. The desired dose should be given by intravenous infusion over a period of at least 60 minutes. If administered over a shorter period of time or in higher concentrations, there is the possibility of inducing marked hypotension in addition to thrombophlebitis. Rapid administration may also produce flushing and a transient rash over the neck and shoulders.

2. Continuous infusion (should be used only when intermittent infusion is not feasible). 1-2g can be added to a sufficiently large volume of sodium chloride intravenous infusion or 5% dextrose intravenous infusion to permit the desired daily dose to be administered slowly by intravenous drip over a 24 hour period.

3. Oral administration

The contents of vials for parenteral administration may be used.

Common flavouring syrups may be added to the solution at the time of administration to improve the taste.

Vials are for single use only and any unused product or waste material should be disposed of immediately in accordance with local requirements.

7. Marketing Authorisation Holder

Wockhardt UK Limited

Ash Road North

Wrexham LL13 9UF

United Kingdom

8. Marketing Authorisation Number(S)

PL 29831/0322

9. Date Of First Authorisation/Renewal Of The Authorisation

Date of first authorisation: 4 April 2008

10. Date Of Revision Of The Text

Capozide 25/15

Generic Name: hydrochlorothiazide and captopril (hye droe klor oh THY a zide and KAP toe pril)

Brand Names: Capozide 25/15, Capozide 25/25, Capozide 50/15, Capozide 50/25

What is Capozide 25/15 (hydrochlorothiazide and captopril)?

Hydrochlorothiazide is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention.

Captopril is in a group of drugs called ACE inhibitors. ACE stands for angiotensin converting enzyme. Captopril lowers blood pressure and also relieves symptoms of fluid retention.

The combination of hydrochlorothiazide and captopril is used to treat hypertension (high blood pressure).

Hydrochlorothiazide and captopril may also be used for purposes not listed in this medication guide.

What is the most important information I should know about Capozide 25/15 (hydrochlorothiazide and captopril)?

You should not use this medication if you are allergic to hydrochlorothiazide or captopril, or if you have a history of asthma or allergies, or you are unable to urinate.

You should not use this medication if you are allergic to any other ACE inhibitor, such as benazepril (Lotensin), fosinopril (Monopril), enalapril (Vasotec), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), or trandolapril (Mavik).

Before taking hydrochlorothiazide and captopril, tell your doctor if you have kidney disease (or are on dialysis), liver disease, glaucoma, congestive heart failure, gout, lupus, diabetes, or an allergy to sulfa drugs or penicillin.

Do not use hydrochlorothiazide and captopril if you are pregnant. It could harm the unborn baby.

Do not use potassium supplements or salt substitutes while you are taking hydrochlorothiazide and captopril, unless your doctor has told you to.

Conditions that may cause very low blood pressure include: vomiting, diarrhea, heavy sweating, heart disease, dialysis, a low-salt diet, or taking diuretics (water pills). Follow your doctor's instructions about the type and amount of liquids you should drink while taking hydrochlorothiazide and captopril. Tell your doctor if you have a prolonged illness that causes diarrhea or vomiting.

What should I discuss with my healthcare provider before taking Capozide 25/15 (hydrochlorothiazide and captopril)?

Do not use this medication if you are allergic to hydrochlorothiazide or captopril, or if you have:

• 
  

  a history of asthma or allergies; or

  
  


• 
  

  if you are unable to urinate.

  
  

You should not use this medication if you are allergic to any other ACE inhibitor, such as benazepril (Lotensin), fosinopril (Monopril), enalapril (Vasotec), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), or trandolapril (Mavik).

To make sure you can safely take hydrochlorothiazide and captopril, tell your doctor if you have any of these other conditions:

• kidney disease (or if you are on dialysis);


• liver disease;


• 
  

  glaucoma;

  
  


• 
  

  congestive heart failure;

  
  


• 
  

  gout;

  
  


• 
  

  lupus;

  
  


• 
  

  diabetes; or

  
  


• 
  

  an allergy to sulfa drugs or penicillin

  
  

FDA pregnancy category D. Do not use hydrochlorothiazide and captopril if you are pregnant. It could harm the unborn baby. Stop using this medication and tell your doctor right away if you become pregnant. Use effective birth control while taking hydrochlorothiazide and captopril. Hydrochlorothiazide can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take Capozide 25/15 (hydrochlorothiazide and captopril)?

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Your doctor may occasionally change your dose to make sure you get the best results.

Take each dose with a full glass of water.

Conditions that may cause very low blood pressure include: vomiting, diarrhea, heavy sweating, heart disease, dialysis, a low-salt diet, or taking diuretics (water pills). Follow your doctor's instructions about the type and amount of liquids you should drink while taking hydrochlorothiazide and captopril. Tell your doctor if you have a prolonged illness that causes diarrhea or vomiting.

Your blood pressure will need to be checked often. Your blood and urine may also be tested if you have been vomiting or are dehydrated. Visit your doctor regularly.

Hydrochlorothiazide can interfere with the results of a thyroid test. Tell any doctor who treats you that you are using a thiazide diuretic.

Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.

Store at room temperature away from moisture, heat, and light.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, weakness, dizziness, dry mouth, thirst, muscle pain or weakness, or feeling like you might pass out.

What should I avoid while taking Capozide 25/15 (hydrochlorothiazide and captopril)?

Avoid becoming overheated or dehydrated during exercise and in hot weather. Follow your doctor's instructions about the type and amount of liquids you should drink. In some cases, drinking too much liquid can be as unsafe as not drinking enough.

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall. Drinking alcohol can further lower your blood pressure and may increase certain side effects of hydrochlorothiazide and captopril.

Do not use potassium supplements or salt substitutes while you are taking hydrochlorothiazide and captopril, unless your doctor has told you to.

Capozide 25/15 (hydrochlorothiazide and captopril) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; severe stomach pain; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

• 
  

  eye pain, vision problems;

  
  


• 
  

  high potassium (slow heart rate, weak pulse, muscle weakness, tingly feeling);

  
  


• 
  

  low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling);

  
  


• 
  

  dry mouth, thirst, nausea, vomiting;

  
  


• 
  

  feeling weak, drowsy, restless, or light-headed;

  
  


• 
  

  a red, blistering, peeling skin rash;

  
  


• 
  

  jaundice (yellowing of the skin or eyes);

  
  


• 
  

  urinating less than usual or not at all;

  
  


• 
  

  swelling, weight gain, feeling short of breath; or

  
  


• 
  

  fever, chills, body aches, flu symptoms.

  
  

Less serious side effects may include:

• 
  

  cough;

  
  


• 
  

  dizziness, headache, tired feeling;

  
  


• 
  

  blurred vision;

  
  


• 
  

  diarrhea, constipation, upset stomach; or

  
  


• 
  

  mild skin rash, increased sweating.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Capozide 25/15 (hydrochlorothiazide and captopril)?

Cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety can add to the side effects of hydrochlorothiazide and captopril. Tell your doctor if you regularly use any of these medicines, or any other blood pressure medications.

Tell your doctor about all other medicines you use, especially:

• 
  

  gold injections to treat arthritis;

  
  


• 
  

  other diuretics (water pills) or blood pressure medications;

  
  


• 
  

  lithium (Lithobid, Eskalith);

  
  


• 
  

  a blood thinner such as warfarin (Coumadin, Jantoven);

  
  


• 
  

  digoxin (Lanoxin);

  
  


• 
  

  nitroglycerin (Nitrolingual, Nitrostat, Nitro-Dur, and others);

  
  


• 
  

  cholestyramine (Prevalite, Questran) or colestipol (Colestid);

  
  


• 
  

  steroids (prednisone and others);

  
  


• 
  

  NSAIDs (non-steroidal anti-inflammatory drugs) such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Arthrotec, Cambia, Cataflam, Voltaren, Flector Patch, Pennsaid, Solareze), indomethacin (Indocin), meloxicam (Mobic), and others; or

  
  


• 
  

  insulin or diabetes medicine taken by mouth.

  
  

This list is not complete and other drugs may interact with hydrochlorothiazide and captopril. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More Capozide 25/15 resources

• Capozide 25/15 Side Effects (in more detail)
• Capozide 25/15 Use in Pregnancy & Breastfeeding
• Drug Images
• Capozide 25/15 Drug Interactions
• Capozide 25/15 Support Group
• 0 Reviews for Capozide 25/15 - Add your own review/rating

• Capozide 25/15 Advanced Consumer (Micromedex) - Includes Dosage Information

Compare Capozide 25/15 with other medications

• Heart Failure
• High Blood Pressure

Where can I get more information?

• Your pharmacist can provide more information about hydrochlorothiazide and captopril.

See also: Capozide 25/15 side effects (in more detail)

Murocoll 2

Pronunciation: fen-il-EF-rin/skoe-PAHL-ah-meen
Generic Name: Phenylephrine/Scopolamine
Brand Name: Murocoll 2

Murocoll 2 is used for:

Temporarily dilating the pupil and paralyzing certain parts of the eye for diagnostic procedures. It may be used before or after surgery to treat certain types of eye inflammation. It may also be used for other conditions as determined by your doctor.

Murocoll 2 is an adrenergic and anticholinergic combination. It works by stopping the eye muscles from reacting to certain substances found in the body, which causes the pupil to dilate (widen).

Do NOT use Murocoll 2 if:

• you are allergic to any ingredient in Murocoll 2


• you have glaucoma or you are at risk for glaucoma

Contact your doctor or health care provider right away if any of these apply to you.

Before using Murocoll 2:

Some medical conditions may interact with Murocoll 2. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have blockage of your bladder, heart problems, an overactive thyroid, nerve problems, trouble urinating, high blood pressure, severe blood vessel problems, or diabetes

Some MEDICINES MAY INTERACT with Murocoll 2. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Monoamine oxidase inhibitors (MAOIs) (eg, phenelzine) because severe high blood pressure may occur


• Phenothiazines (eg, thioridazine) because their effectiveness may be decreased by Murocoll 2

This may not be a complete list of all interactions that may occur. Ask your health care provider if Murocoll 2 may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Murocoll 2:

Use Murocoll 2 as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Murocoll 2 is only for the eye. Do not get it in your nose or mouth.


• To use Murocoll 2 in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.


• To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.


• If you miss a dose of Murocoll 2, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Murocoll 2.

Important safety information:

• Murocoll 2 may cause drowsiness or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Murocoll 2 with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Some of these products contain sulfites. Sulfites may cause an allergic reaction in some patients (eg, asthma patients). If you have ever had an allergic reaction to sulfites, ask your pharmacist if your product has sulfites in it.


• Murocoll 2 may make your eyes more sensitive to sunlight. It may help to wear sunglasses.


• If you have an appointment for an eye examination and your doctor has told you that you will receive Murocoll 2, be sure to make arrangements to have someone drive you home in case your vision is blurry.


• Murocoll 2 should not be used in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Murocoll 2 while you are pregnant. It is not known if Murocoll 2 is found in breast milk. Do not breast-feed while using Murocoll 2.

Possible side effects of Murocoll 2:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Blurred vision; burning, stinging, or redness; drowsiness; dry mouth; inflammation.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; eye pain; eye pus; fever; flushing or dryness of the skin; irregular or rapid heartbeat; visual hallucinations.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Murocoll 2 side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Murocoll 2 may be harmful if swallowed.

Proper storage of Murocoll 2:

Store Murocoll 2 at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Murocoll 2 out of the reach of children and away from pets.

General information:

• If you have any questions about Murocoll 2, please talk with your doctor, pharmacist, or other health care provider.


• Murocoll 2 is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Murocoll 2. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Murocoll 2 resources

• Murocoll 2 Side Effects (in more detail)
• Murocoll 2 Use in Pregnancy & Breastfeeding
• Murocoll 2 Drug Interactions
• Murocoll 2 Support Group
• 0 Reviews · Be the first to review/rate this drug

Diclotal

Diclotal may be available in the countries listed below.

Ingredient matches for Diclotal

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclotal in the following countries:

• Ethiopia


• Sri Lanka

International Drug Name Search

Alertop

Alertop may be available in the countries listed below.

Ingredient matches for Alertop

Cetirizine

Cetirizine is reported as an ingredient of Alertop in the following countries:

• Chile

International Drug Name Search

Dextromethorphan/Guaifenesin/Phenylephrine Drops

Generic Name: Dextromethorphan/Guaifenesin/Phenylephrine (dex-troe-meth-OR-fan/gwye-FEN-e-sin/fen-ill-EF-rin)
Brand Name: Examples include Nortuss-DE and Zotex Pediatric

Dextromethorphan/Guaifenesin/Phenylephrine Drops are used for:

Relieving congestion, cough, and throat and airway irritation due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.

Dextromethorphan/Guaifenesin/Phenylephrine Drops are a decongestant, cough suppressant, and expectorant combination. It works by constricting blood vessels and reducing swelling in the nasal passages, loosening mucus and lung secretions in the chest, and making coughs more productive. It also works in the brain to help decrease the cough reflex to reduce a dry cough.

Do NOT use Dextromethorphan/Guaifenesin/Phenylephrine Drops if:

• you are allergic to any ingredient in Dextromethorphan/Guaifenesin/Phenylephrine Drops


• you have severe high blood pressure, rapid heartbeat, or other severe heart problems (eg, heart blood vessel disease)


• you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dextromethorphan/Guaifenesin/Phenylephrine Drops:

Some medical conditions may interact with Dextromethorphan/Guaifenesin/Phenylephrine Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of glaucoma, an enlarged prostate gland or other prostate problems, heart problems, diabetes, high blood pressure, blood vessel problems, adrenal gland problems, an overactive thyroid, seizures, or stroke


• if you have a chronic cough, lung problems (eg, asthma, chronic bronchitis, emphysema), or chronic obstructive pulmonary disease (COPD), or if cough occurs with large amounts of mucus

Some MEDICINES MAY INTERACT with Dextromethorphan/Guaifenesin/Phenylephrine Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Beta-blockers (eg, propranolol), COMT inhibitors (eg, tolcapone), furazolidone, indomethacin, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because the risk of side effects from Dextromethorphan/Guaifenesin/Phenylephrine Drops may be increased


• Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased


• Bromocriptine because the risk of side effects may be increased by Dextromethorphan/Guaifenesin/Phenylephrine Drops


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Dextromethorphan/Guaifenesin/Phenylephrine Drops

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dextromethorphan/Guaifenesin/Phenylephrine Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dextromethorphan/Guaifenesin/Phenylephrine Drops:

Use Dextromethorphan/Guaifenesin/Phenylephrine Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Dextromethorphan/Guaifenesin/Phenylephrine Drops may be taken with or without food.


• Drink plenty of water while taking Dextromethorphan/Guaifenesin/Phenylephrine Drops.


• Use the dropper that comes with Dextromethorphan/Guaifenesin/Phenylephrine Drops to measure your dose. Ask your pharmacist for help if you are unsure of how to measure your dose.


• If you miss a dose of Dextromethorphan/Guaifenesin/Phenylephrine Drops, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dextromethorphan/Guaifenesin/Phenylephrine Drops.

Important safety information:

• Dextromethorphan/Guaifenesin/Phenylephrine Drops may cause dizziness or drowsiness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Dextromethorphan/Guaifenesin/Phenylephrine Drops. Using Dextromethorphan/Guaifenesin/Phenylephrine Drops alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.


• Do not take appetite suppressants while you are taking Dextromethorphan/Guaifenesin/Phenylephrine Drops without checking with your doctor.


• Dextromethorphan/Guaifenesin/Phenylephrine Drops contains phenylephrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains phenylephrine. If it does or if you are uncertain, contact your doctor or pharmacist.


• Do NOT exceed the recommended dose or take Dextromethorphan/Guaifenesin/Phenylephrine Drops for longer than prescribed without checking with your doctor.


• If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.


• Dextromethorphan/Guaifenesin/Phenylephrine Drops may interfere with certain lab test results. Make sure that all of your doctors and lab personnel know that you are taking Dextromethorphan/Guaifenesin/Phenylephrine Drops.


• Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Dextromethorphan/Guaifenesin/Phenylephrine Drops.


• Use Dextromethorphan/Guaifenesin/Phenylephrine Drops with caution in the ELDERLY because they may be more sensitive to its effects.


• Caution is advised when using Dextromethorphan/Guaifenesin/Phenylephrine Drops in CHILDREN because they may be more sensitive to its effects.


• PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Dextromethorphan/Guaifenesin/Phenylephrine Drops, discuss with your doctor the benefits and risks of using Dextromethorphan/Guaifenesin/Phenylephrine Drops during pregnancy. It is unknown if Dextromethorphan/Guaifenesin/Phenylephrine Drops are excreted in breast milk. Do not breast-feed while taking Dextromethorphan/Guaifenesin/Phenylephrine Drops.

Possible side effects of Dextromethorphan/Guaifenesin/Phenylephrine Drops:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; excitability; headache; nausea; nervousness or anxiety; trouble sleeping; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.

See also: Dextromethorphan/Guaifenesin/Phenylephrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (http://www.aapcc.org/DNN/), or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Dextromethorphan/Guaifenesin/Phenylephrine Drops:

Store Dextromethorphan/Guaifenesin/Phenylephrine Drops at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dextromethorphan/Guaifenesin/Phenylephrine Drops out of the reach of children and away from pets.

General information:

• If you have any questions about Dextromethorphan/Guaifenesin/Phenylephrine Drops, please talk with your doctor, pharmacist, or other health care provider.


• Dextromethorphan/Guaifenesin/Phenylephrine Drops are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Dextromethorphan/Guaifenesin/Phenylephrine Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dextromethorphan/Guaifenesin/Phenylephrine resources

• Dextromethorphan/Guaifenesin/Phenylephrine Side Effects (in more detail)
• Dextromethorphan/Guaifenesin/Phenylephrine Use in Pregnancy & Breastfeeding
• Dextromethorphan/Guaifenesin/Phenylephrine Drug Interactions
• Dextromethorphan/Guaifenesin/Phenylephrine Support Group
• 0 Reviews for Dextromethorphan/Guaifenesin/Phenylephrine - Add your own review/rating

Compare Dextromethorphan/Guaifenesin/Phenylephrine with other medications

• Cough and Nasal Congestion